Who Paid My Doc
Jeralyn Brossfield
Gynecology Rancho Mirage, CA Medical Doctor
NPI 1073689683 CMS profile 1020359
72301 Country Club Dr Ste 104, Rancho Mirage, CA 92270
General payments
$12,873
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Jeralyn Brossfield of Rancho Mirage, CA is reported in the CMS Open Payments database as having received $12,873 across 14 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 92nd percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $11,546 | 6 | |
| 2022 | General | $1,293 | 6 | |
| 2019 | General | $34 | 2 |
Beside peers
- Jeralyn Brossfield
- Gynecology median
- Middle half of Gynecology
- National median
In program year 2025, general payments to Jeralyn Brossfield were reported at $0. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.
Show as a table
| Year | Jeralyn Brossfield | Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $34 | $199 | $66–$472 | $163 |
| 2020 | $0 | $114 | $42–$287 | $114 |
| 2021 | $0 | $141 | $42–$430 | $132 |
| 2022 | $1,293 | $173 | $52–$532 | $149 |
| 2023 | $11,546 | $170 | $57–$501 | $160 |
| 2024 | $0 | $157 | $50–$424 | $164 |
| 2025 | $0 | $162 | $56–$501 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
445
Drug cost
$16,291
Branded share of claims
29.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Colesevelam Hcl | Generic | 49 | $3,739 | |
| Estradiol (Twice Weekly) Estradiol | Brand | 44 | $2,983 | |
| Liothyronine Sodium | Generic | 77 | $2,191 | |
| Progesterone Progesterone, Micronized | Brand | 50 | $1,586 | |
| Dotti Estradiol | Brand | 21 | $1,276 | |
| Levothyroxine Sodium | Generic | 122 | $1,085 | |
| Nystatin | Generic | 12 | $1,037 | |
| Estradiol | Generic | 12 | $1,022 | |
| Valacyclovir Valacyclovir Hcl | Brand | 15 | $1,005 | |
| Sertraline Hcl | Generic | 11 | $157 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gynecology in California
Related records
Gynecology in California
Practitioners in the same specialty and state, ranked by reported value.
All Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.